UK – Amryt’s Myalepta scores NICE backing for rare lipid disorder

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Amryt Pharma’s Myalepta (metreleptin) for use within the NHS.

Myalepta has been recommended for the treatment of the rare lipid disorder lipodystrophy, which is characterised by an abnormal distribution of fat in the body.

It is indicated for use as an adjunct to diet as replacement therapy for the treatment of leptin deficiency in patients with congenital or acquired general lipodystrophy (GL) in adults and children aged two years and above…